Description du projet
Un processeur de tissu innovant pour obtenir un diagnostic rapide
Le traitement tissulaire est une procédure laborieuse qui prend plus de 24 heures et utilise des produits chimiques dangereux. Le principal objectif du projet Origin, financé par l’UE, est de commercialiser un dispositif innovant qui réduit le nombre d’étapes de traitement et de produits chimiques utilisés. Plus important encore, les déchets chimiques peuvent être mis au rebut de manière respectueuse de l’environnement, et l’utilisation du dispositif en lui-même est moins coûteuse. Le projet entreprendra les activités nécessaires visant à valider et à optimiser plus avant le dispositif, au-delà du stade de prototype, afin de proposer des diagnostics et des résultats plus rapides dans un cadre clinique.
Objectif
Current tissue processors on the market take up to 24 hours to process samples for diagnosis and leave the operator exposed to chemical fumes. They also use different kinds of chemicals, in large volumes, which leads to cross contamination of chemicals and samples. This results in more plastic packaging to dispose of, making the process both costly and environmental unfriendly. Our company, DIAPATH SpA, is developing an innovative solution to these problems - the E-Processor. DIAPATH has been in the tissue processing industry since 1997 and currently has a turnover of €12Million and 100 employees. The E-Processor reduces the number of processing steps, and reduces the number of chemicals used. The operator will be safeguarded from chemical fumes and chemical containers will now be disposed of in a safe and environmentally friendly way. Our value proposition is, less operating costs due to reduced chemicals and packaging, faster diagnosis and results for patients. Our target users are Hospitals and Diagnostics Laboratories. The current global diagnostics market is estimated at €243.59 Million and expected to reach €378 Million by year 2025. Our entry point for our innovation will be the European market, where we already have significant market share. We will be using our extensive distribution chain to bring our innovation to international markets. Our innovation is currently at prototype stage with a compact functional machine. Further validation and tests remain to be done to bring it to market. The purpose of the phase 1 is to carry out feasibility studies before commercialisation. This will allow us to come up with a detailed business plan covering a projected five-year period. This innovation will grow our market share from 30% and increase our turnover to €50million by 2023. It will also create 15 new jobs.
Champ scientifique
- engineering and technologyenvironmental engineeringwaste management
- social scienceseconomics and businesseconomicsproduction economicsproductivity
- medical and health sciencesclinical medicineoncology
- natural scienceschemical sciencesorganic chemistryalcohols
- natural sciencescomputer and information sciencesartificial intelligencemachine learningdeep learning
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
24057 Martinengo (Bg)
Italie
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.